βhCG as a prognostic marker in adenocarcinoma of the prostate

M T Sheaff, J E Martin, D F Badenoch, S I Baithun

Abstract

Aims—To assess the importance of immunohistological detection of β-human chorionic gonadotrophin (βhCG) in localised prostatic adenocarcinoma with regard to prognosis and clinical applications. Methods—Eighty consecutive cases of clinically localised adenocarcinoma of the prostate were studied retrospectively. Immunohistological analysis on formalin fixed, paraffin wax embedded prostate tissue from transurethral resection was related to clinical outcome and survival. Prognosis was also related to tumour grade.

Results—βhCG was detected in 12 cases. Nine of these patients were found to have metastases (75%) at follow up and 11 (92%) were dead within 18 months. There was no correlation with grade and prognosis in this group. Of the 68 βhCG negative cases, 21 had developed metastases (31%) and 25 (37%) had died within 18 months. In the βhCG negative group there was an association between histological grade and survival.

Conclusion—The demonstration of βhCG in prostatic adenocarcinoma identifies a group of patients with poor prognosis, irrespective of histological grade. This additional information will be extremely valuable in the subsequent clinical management of such patients.

Keywords: prostate, adenocarcinoma, β-human chorionic gonadotrophin, prognosis.

The clinical management of prostatic adenocarcinoma remains controversial despite the use of grading systems to predict prognosis. The Gleason score is widely used, but unfortunately is not always accurate enough to discriminate between those patients who should be observed, and those who require active treatment by radical surgery, irradiation or hormone therapy. A reliable test that predicts the likelihood of tumour progression would be of enormous benefit in planning treatment of these patients.

Neuroendocrine cells are well described in both normal and neoplastic prostatic tissue.1 Many hormones have been identified in these cells, including β-human chorionic gonadotrophin (βhCG).2-4 The presence of these neuroendocrine cells has not previously been regarded as being of clinical importance. The β subunit of the peptide hormone hCG has also been identified in a variety of germ cell and non-germ cell tumours, and in the former is used to monitor response to treatment and to detect tumour relapse. The significance of positivity in non-germ cell malignancies has been unclear until recently, when it has been found that the presence of βhCG is related to poor response to radiotherapy56 and poor prognosis in transitional cell carcinomas of the bladder.7 βhCG has also been suggested as a biological marker of prognostic significance in colonic adenocarcinoma.

We therefore investigated the presence of βhCG immunohistochemically in tissue sections of clinically localised prostatic adenocarcinoma and related this to tumour grade and prognosis.

Methods

Eighty consecutive patients with clinically localised adenocarcinoma of the prostate, treated at the Royal London Hospital between 1980 and 1985, were studied. The mean age was 69 years (range 58–84 years). Follow up was available for each patient for a mean of 58 months (range 12–120 months).

Tumour was resected transurethrally and the specimens obtained were fixed in 10% formal saline. The weight of tissue resected ranged from 5 to 90 g and between one and 10 blocks were embedded in paraffin wax. Sections 4 μm thick were cut and stained with haematoxylin and eosin. Tumour sections were independently assessed by two histopathologists and graded according to the Gleason system giving a score from 2 to 10. Those patients with a low Gleason score (2–4; group 1) were managed by surveillance. Those with higher Gleason score (>4) were offered radical radiotherapy. These were further subdivided into two groups: Gleason scores 5 and 6 (group 2) and 7–10 (group 3). In general, hormone manipulation was reserved for those patients who re-presented with painful metastases.

For immunohistochemistry, a random section from each case was dewaxed, placed in 0·3% hydrogen peroxide and methanol for 15 minutes at room temperature. The sections were then washed in TRIS buffer at pH 7·6 and subsequently incubated with normal swine serum for 10 minutes. Sections were then overlaid with rabbit anti-βhCG (Dako, High Wycombe, UK) for 20 minutes and incubated with peroxidase conjugated swine anti-rabbit immunoglobulin (Dako) for a further 20 minutes. The peroxidase complex was visualised using 3,3′diaminobenzidine and hydrogen peroxidase. Mayer’s solution was used as counterstain.
Results

The results of βhCG immunohistochemistry are presented in tables 1 and 2. Twelve patients had tumours positive for βhCG (figs 1 and 2). Of the 68 patients with tumours not expressing βhCG, only 21 (31%) developed metastases. Twenty-five (37%) of these patients had died within 18 months. In this group there was strong correlation between survival and Gleason score (p<0.009; table 2).

Of the patients in the βhCG positive group, nine (75%) developed metastases and 11 (92%) of the 12 were dead within 18 months (p<0.004 and p<0.0002, respectively; table 1). There was no correlation between Gleason score and prognosis in this group of patients (p<0.13).

Discussion

The management of clinically localised prostatic adenocarcinoma remains difficult despite grading systems aimed at discriminating between those patients with tumours that should be treated aggressively, and those who should be treated symptomatically. Grading and staging systems offer some predictive value, but unfortunately they do not identify those patients with localised disease who progress rapidly and who would probably not benefit from conventional therapeutic regimens. A more reliable predictor of the likelihood of tumour progression would be of enormous benefit in planning the selection of appropriate treatment of patients with localised disease.

Neuroendocrine cells are present in the normal and neoplastic prostate gland and have also been described in the prostatic urothelium. They are easily identified in tissue sections using chromogranin or neuron specific enolase markers. A variety of hormones have been demonstrated immunohistochemically within these cells, most commonly serotonin and calcitonin. βhCG has also been detected in several published series (table 3). The significance of their presence is uncertain, but it has been suggested that they have an endocrine/paracrine role in growth and development.

βhCG has been recognised in many human malignancies and in some has been related to poor prognosis. In fact, we have shown previously that detection of βhCG in transitional carcinomas of the bladder is related to both poor prognosis and poor response to radiotherapy (especially if there is also squamous metaplasia12). Campo et al.13 also showed that βhCG was related to worse prognosis in colorectal carcinomas. Possible reasons for this association were not proposed. Very high serum levels of βhCG (>50 000 IU/l) also indicate a worse prognosis in germ cell tumours of the testis.14

In addition to immunohistochemical demonstration in tissue sections of prostate tumours, βhCG concentrations are also increased in both serum and urine from patients with adenocarcinoma of the prostate (table 3). However, few of these studies have specifically related the presence of βhCG to survival and none have done so by measuring urinary βhCG concentrations.

Clinical outcome was related to both Gleason score (grade) and results of βhCG immunohistochemistry. $\chi^2$ statistics were performed on the data.
Yamanaka et al. did not detect urinary βhCG in their series of prostatic carcinomas (using β core fragment antisera). IHC = immunohistochemistry.

Of the 80 cases studied in this investigation, 12 were positive for βhCG in neoplastic epithelial cells of tissue sections. This was found to be related with poor prognosis, irrespective of histological grade. Those tumours that were βhCG negative did show close correlation with histological grade. The fact that βhCG is raised in both serum and urine of patients with prostate cancer suggests that the immunohistochemical detection of this hormone is not artefactual, and that the tumour cells are actually producing and secreting it.

βhCG increases both serum and prostatic tissue concentrations of testosterone and prostatic carcinoma is responsive to androgenic stimuli. βhCG may therefore be promoting tumour growth indirectly by increasing testosterone concentrations. (Testosterone is also associated with increased prostatic blood flow.) In fact, orchidectomy, anti-androgens and oestrogens have been useful in arresting (or at least retarding) the progression of more advanced prostatic tumour. In addition to a hormonally induced action, βhCG may also have a more direct paracrine effect on tumour growth. It has recently been discovered that βhCG prolongs survival of cultured transitional carcinoma cells (and has a structure similar to platelet derived growth factor; Iles and Gillett, personal communication). It seems that this increased survival is not due to a proliferative mechanism, but may be due to blocking of apoptosis. It is tempting to speculate that this may in some way relate to bcl-2 expression (an anti-apoptosis protein) as the latter is found in non-androgen dependent prostate cancers and androgen withdrawal has been shown to induce apoptosis. A further possibility is that βhCG confers tumour cells with a metastasising advantage over the surrounding negative cells by some as yet unknown mechanism.

Another tumour marker, c-erb-B2, has recently been shown to be associated with decreased survival in prostate cancer, being a finding in common with other epithelial tumours. The latter is becoming an important and useful tool in the management of breast carcinoma and in fact immunohistochemistry for this marker is routinely performed on breast tumours in our department prior to planning chemotherapy. For similar reasons, it may be that this marker will be investigated routinely in prostatic tumours. It is likely, however, that βhCG or a combination of erb-B2 and βhCG immunohistochemistry will provide more information for the clinician to base therapeutic decisions upon. βhCG may in fact be of more use clinically as it is easily detected in urine. This would make it a potentially more widely acceptable and simpler method. In fact, one of the few available tumour markers that may be useful for screening high risk populations.

In conclusion, the immunohistochemical detection of βhCG may be helpful in discriminating those localised tumours that would not benefit from current treatment regimens. These patients would therefore be better managed by either more conservative measures or conversely may benefit from more aggressive chemotherapy or more radical surgery, or both.

Dr Michael Sheaff is supported by the Ernst Schering Research Foundation. Dr Joanne Martin is a Wellcome Trust Fellow.

## Table 3 βhCG in adenocarcinoma of the prostate: review of the literature

<table>
<thead>
<tr>
<th>Year</th>
<th>Reference</th>
<th>Number of cases</th>
<th>Detection method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1976</td>
<td>McManus et al.</td>
<td>1</td>
<td>IHC</td>
<td>? Prognosis</td>
</tr>
<tr>
<td>1977</td>
<td>Broder et al.</td>
<td>1</td>
<td>Serum</td>
<td>All stage D</td>
</tr>
<tr>
<td>1980</td>
<td>Papapetrou et al.</td>
<td>2</td>
<td>Urine</td>
<td>? Prognosis</td>
</tr>
<tr>
<td>1983</td>
<td>Fukunati et al.</td>
<td>3</td>
<td>Urine, serum 2</td>
<td>? Prognosis</td>
</tr>
<tr>
<td>1984</td>
<td>Prentiss et al.</td>
<td>1</td>
<td>IHC</td>
<td>? Prognosis</td>
</tr>
<tr>
<td>1986</td>
<td>Feinsetz et al.</td>
<td>2</td>
<td>IHC</td>
<td>? Prognosis</td>
</tr>
<tr>
<td>1987</td>
<td>Abrahamson et al.</td>
<td>11</td>
<td>IHC</td>
<td>Subunit detected</td>
</tr>
<tr>
<td>1987</td>
<td>Shah et al.</td>
<td>9</td>
<td>IHC</td>
<td>Eight poorly</td>
</tr>
<tr>
<td>1988</td>
<td>Oliver et al.</td>
<td>2</td>
<td>IHC</td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Bostwick et al.</td>
<td>26</td>
<td>IHC</td>
<td></td>
</tr>
</tbody>
</table>
beta hCG as a prognostic marker in adenocarcinoma of the prostate.

M T Sheaff, J E Martin, D F Badenoch and S I Baithun

doi: 10.1136/jcp.49.4.329

Updated information and services can be found at:
http://jcp.bmj.com/content/49/4/329

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/